MaxVal Releases Max-IDS™ 4.0.2

MaxVal announces the latest upgrade to its information disclosure statement software, Max-IDS, version 4.0.2.

Continue reading

Hot Topics in Tech | September 2018 Newsletter | Maxval

This issue covers cardiovascular diseases and discloses the technological categories and products related to the use of renal denervation approach for managing hypertension. It also talks about the three main categories of Artificial Intelligence namely Artificial Narrow Intelligence (ANI), Artificial General Intelligence (AGI), and Artificial Super Intelligence (ASI). They influence human life in the form of automated cars, virtual assistants, image recognition software, robotics, games, life science and so on. Read more on this report.

Continue reading

MaxVal Announces symphony® 1.5 – The Latest Version of Its Intellectual Property Management System

MaxVal announces the latest upgrade to its advanced, cloud-based IP management platform, symphony®.

Since its launch in 2016, symphony® has revolutionized IP management through its innovative use of Salesforce.com’s Lightning platform, delivering the industry’s most advanced workflow and automation capabilities; all in a highly configurable, intuitive system, designed for the modern IP department.

Continue reading

Hot Topics in Tech | August 2018 Newsletter | Maxval

In this issue, we have covered a couple of hot topics that are currently trending in the biotech and blockchain technology industries. We have highlighted Illumina’s Q2 results and provided some
insights about the company alongwith a quick run-through of the firm's recent collaborations in China. Illumina reported a revenue of $830 million in Q2 which is a 25% increase compared to $662 million in the same quarter of 2017. Illumina’s biggest advantage over its competitors lies in its technology diversification.

Continue reading

Hot Topics in Tech | June 2018 Newsletter | Maxval

In this issue, we have covered a couple of hot topics that are currently trending in the biotech and cloud-tech industries. We have talked about the FDA's approval of tisagenlecleucel (KYMRIAH, Novartis Pharmaceuticals Corp.), a CD19-directed genetically modified autologous T-cell immunotherapy, to include treatment of patients with relapsed or refractory large B-cell lymphoma. Tisagenlecleucel is the only CAR T-cell therapy to receive FDA approval for two distinct indications. The report includes a chart of major commercial players in the CAR T-cell space and a Year-on-Year trend on the number of patents and patent applications from 2012 to 2018.

Continue reading

Technology Landscape Study on CRISPR-Cas9

Although CRISPR was known to have an important role in bacterial immunity for over a decade, it is only in the last 5 years that it has garnered interest as a gene editing tool. Increasing investment in this field is indicative of global market opportunities for CRISPR-Cas9 over existing alternatives.

Continue reading

Recent advances in Life Sciences | May 2018 Newsletter | MaxVal

The article presents a base editing approach to expand the scope and efficiency of CRISPR mediated genome editing.

Continue reading

MaxVal to Sponsor and Exhibit at IPBC Global, San Francisco (June 10-12, 2018)

MaxVal is sponsoring the 11th annual event of IP Business Congress Global (IPBC), to be held from June 10-12, 2018 at Palace Hotel, San Francisco.

Continue reading

Recent advances in Diabetes Management | April 2018 Newsletter | MaxVal

The article addresses Medtronic’s recent FDA approval of the Guardian™ Connect Continuous Glucose Monitoring (CGM) system. A brief overview of all the clinical studies related to CGM has been presented.

Continue reading

MaxVal Exhibits at INTA 140th Annual Meeting, Seattle, WA (May 19-23, 2018)

MaxVal is exhibiting at INTA 140th Annual meeting at Booth #418, to be held from May 19-23 at Washington State Convention Center, Seattle, WA.

Continue reading